Altered nicotinamide adenine dinucleotide metabolism drives cartilage degeneration and osteoarthritis
Clinical and Translational Medicine · 2025-11 · 15 (11)
DOI: 10.1002/ctm2.70513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 06.11.2025. Verfasst von Xiaoxin Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: NAD, Osteoarthritis, Cartilage, Articular. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Background
We previously conducted a comprehensive survey of energy metabolism in osteoarthritis (OA), revealing significant reductions of nicotinamide adenine dinucleotide (NAD + ) levels in OA cartilage. This study aimed to test whether NAD + deficiency present in OA plays a mechanistic role in disease development.
Methods
We conducted integrative analyses across human, murine, and rat OA models to examine NAD⁺ metabolism and its regulatory enzymes. The impact of pharmacological NAD⁺ augmentation (via nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR)) and genetic overexpression of the NAD⁺ biosynthetic enzyme NMN adenosyltransferase (NMNAT1) was tested in surgical and aging‐related OA models. Expression and function of the NAD⁺‐consuming enzyme poly (ADP‐ribose) polymerase 14 (PARP14) were examined via siRNA knockdown in chondrocytes under inflammatory conditions, coupled with metabolic assays and extracellular matrix gene profiling.
Results
NAD + levels were decreased in human and murine OA, accompanied by upregulation of both the NAD + biosynthetic enzyme Nicotinamide phosphoribosyltransferase (NAMPT) and the NAD + consuming enzyme PARP14. While NAMPT expression was elevated, its effect on total NAD⁺ may be offset by increased NAD⁺ consumption or substrate limitation under inflammatory conditions. Treatment with NAD + precursors and transgenic overexpression of NMNAT1 suppressed cartilage disruption during in aging murine and surgical rat model of OA. Increased expression of PARP14 in OA cartilage contributed to NAD + decline and promoted cartilage degeneration.
Conclusions
This study reveals that dysregulated NAD⁺ metabolism, driven by increased PARP14 consumption, constitutes a potential mechanism underlying OA pathogenesis. Our findings support the concept that enhancing NAD⁺ availability via precursors or biosynthetic pathway modulation may offer disease‐modifying effects at the molecular and histological level. Further investigation is needed to determine the functional and translational implications of targeting this pathway. Key points PARP14 is upregulated in OA cartilage and contributes to NAD⁺ depletion. PARP14 silencing restores NAD⁺ levels and represses OA‐related metabolic and matrix‐degrading changes. NAD⁺ precursor treatment and NMNAT1 overexpression protect against cartilage degeneration in aging and post‐traumatic OA models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland, Australia.
- Department of Orthopaedic Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
- Center for AI-Driven Medical Research, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
- Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, Australia.
- Metabolomics Australia (Queensland Node), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, Australia.
- eResearch Office, Queensland University of Technology, Brisbane, Queensland, Australia.
ORCID-Profile: Indira Prasadam
Förderung
- National Health and Medical Research Council
Zitieren
APA
Wu, X., Fan, X., Plan, M., Stark, T., McCubbin, T., Barrero, R. A., Marinova, M., Bertoldo, M. J., Goss, D. M., Wu, L. E., Crawford, R., Mao, X., & Prasadam, I. (2025). Altered nicotinamide adenine dinucleotide metabolism drives cartilage degeneration and osteoarthritis. Clinical and Translational Medicine, 15(11). https://doi.org/10.1002/ctm2.70513
Vancouver
Wu X, Fan X, Plan M, Stark T, McCubbin T, Barrero RA, et al. Altered nicotinamide adenine dinucleotide metabolism drives cartilage degeneration and osteoarthritis. Clinical and Translational Medicine. 2025;15(11). doi:10.1002/ctm2.70513
BibTeX
@article{Wu2025,
author = {Wu, Xiaoxin and Fan, Xiwei and Plan, Manuel and Stark, Terra and McCubbin, Tim and Barrero, Roberto A and Marinova, Maria and Bertoldo, Michael J and Goss, Dale M and Wu, Lindsay E and Crawford, Ross and Mao, Xinzhan and Prasadam, Indira},
title = {Altered nicotinamide adenine dinucleotide metabolism drives cartilage degeneration and osteoarthritis},
journal = {Clinical and Translational Medicine},
year = {2025},
volume = {15},
number = {11},
doi = {10.1002/ctm2.70513}
}
EUVIMED